HLB Co., Ltd. (KOSDAQ:028300)
49,100
+800 (1.66%)
At close: Dec 5, 2025
HLB Co., Ltd. Revenue
HLB Co., Ltd. had revenue of 22.11B KRW in the quarter ending September 30, 2025, with 30.43% growth. This brings the company's revenue in the last twelve months to 80.73B, up 55.49% year-over-year. In the year 2024, HLB Co., Ltd. had annual revenue of 68.13B with 58.80% growth.
Revenue (ttm)
80.73B
Revenue Growth
+55.49%
P/S Ratio
80.02
Revenue / Employee
514.22M
Employees
157
Market Cap
6,460.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68.13B | 25.23B | 58.80% |
| Dec 31, 2023 | 42.90B | -136.81B | -76.13% |
| Dec 31, 2022 | 179.71B | 109.88B | 157.37% |
| Dec 31, 2021 | 69.83B | 13.65B | 24.30% |
| Dec 31, 2020 | 56.18B | 17.76B | 46.22% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |